Regular Research ArticlesA Double-Blind Comparison of Citalopram and Risperidone for the Treatment of Behavioral and Psychotic Symptoms Associated With Dementia
Section snippets
Setting and Participants
Participants of this 12-week clinical trial were recruited upon admission to the geropsychiatric unit of an academic hospital providing treatment to a large urban and suburban population. If they improved sufficiently, participants were discharged to nursing homes, personal care homes, or residential homes for continued treatment under double-blind conditions.
Admissions were eligible if they had a dementia of the Alzheimer type (DAT), vascular dementia, dementia with Lewy bodies, mixed
RESULTS
Of the randomized participants, 53 were randomized to citalopram and 50 to risperidone. The sex distribution and baseline NBRS total scores differed significantly between the two groups (Table 1). Thirty participants continued a stable dose of a cholinesterase inhibitor: 16 (30.2%) randomized to citalopram and 14 (28.0%) randomized to risperidone (Fisher exact p = 0.83). No participant was on memantine during the study. Mean (SD) maximum doses were 31.1 (8.7) mg/day of citalopram and 1.36
DISCUSSION
In patients with dementia hospitalized for the treatment of behavioral or psychotic symptoms, citalopram and risperidone had similar efficacy but citalopram was associated with a lower burden of side effects. To our knowledge, this study is the first head-to-head comparison of a selective serotonin reuptake inhibitor (SSRI) and a second-generation (atypical) antipsychotic in the treatment of noncognitive symptoms associated with dementia. Contrary to our hypothesis and conventional beliefs that
CONCLUSION
We urge caution in generalizing the results of a single trial or in extrapolating them to other drugs. Nonetheless, considering the better tolerability of citalopram and concerns regarding increased mortality associated with antipsychotics,5., 6. our findings should encourage the conduct of additional trials of citalopram and other agents in the treatment of behavioral and psychotic symptoms associated with dementia. Given the current view of questionable risk-benefit ratio of second-generation
References (36)
- et al.
Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease
Am J Geriatr Psychiatry
(2006) - et al.
Cornell scale for depression in dementia
Biol Psychiatry
(1988) - et al.
Mini-Mental State Exam: a practical method for grading the cognitive state of patients for the clinician
J Psychiatr Res
(1975) - et al.
Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale (CIRS)
Psychiatry Res
(1992) - et al.
Use of OSWALD for analyzing longitudinal data with informative dropout
Comput Methods Programs Biomed
(2007) - et al.
Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials
Am J Geriatr Psychiatry
(2006) - et al.
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial
Am J Geriatr Psychiatry
(2006) - et al.
Psychosis of Alzheimer's disease and related dementias
Am J Geriatr Psychiatry
(2000) - et al.
The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease
Neuroimage
(2004) - et al.
Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation
Biol Psychiatry
(1998)
Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003
Am J Psychiatry
Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence
JAMA
Using antipsychotic agents in older patients
J Clin Psychiatry
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials
JAMA
Risk of death in elderly users of conventional vs. atypical antipsychotic medications
N Engl J Med
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
N Engl J Med
Comparison of citalopram, perphenazine and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients
Am J Psychiatry
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial
J Clin Psychiatry
Cited by (199)
Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment
2022, Psychiatric Clinics of North AmericaNew trends in pharmacological control of neuropsychiatric symptoms of dementia
2021, Current Opinion in PharmacologyAntidepressant Use and Progression of Mild to Moderate Alzheimer's Disease: Results from the European ICTUS Cohort
2021, Journal of the American Medical Directors Association
This work was supported by grants from the U.S. Public Health Service (MH59666, MH65416, MH69430, M01RR0056) and the Sandra A. Rotman Program in Neuropsychiatry (Toronto).
Presented in part at the 159th Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, May 20 to 25, 2006.
The authors thank Jennifer Maurer of the University of Pittsburgh Medical Center for database management, and Christina Pataky of the Rotman Research Institute at Baycrest for assistance in preparation of the manuscript.
This trial is registered at Clinical Trials.gov (http://www.clinicaltrials.gov/); identifier:NCT00073658.
Richard Blakesley, Kimberly Huber, and Patricia Houck have no conflicts of interest or financial interests to disclose. Sati Mazumdar has directly purchased stocks of Forest. Benoit Mulsant has received grants or Research Support from the National Institute of Health, Eli Lilly, Janssen, and Pfizer. He has been a consultant for Lundbeck and Pfizer. He is on the speakers' bureau of AstraZeneca and Pfizer. He has directly purchased stocks (all below $10,000) of Akzo-Nobel, Alkermes, AstraZeneca, Biogen Idec, Celsion, Elan, Eli Lilly, Forest, General Electric, Immune Response, Pfizer. Bruce Pollock has received grants or research support from the National Institute of Health and Janssen Pharmaceuticals. He has served on the advisory board of Forest Laboratories and is a faculty member of the Lundbeck Institute. He is on the speakers' bureau of Forest and Lundbeck. Jules Rosen is on the speakers' bureau of Forest, Janseen, and Pfizer. He has directly purchased stocks of Forest.